Roxadustat-induced central hypothyroidism in hemodialysis patients: a report of two cases

doi:10.16138/j.1673-6087.2025.06.10

Abstract

Abstract:

Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is a novel class of oral medications for treating renal anemia, but adverse drug events have been reported both in China and internationally in recent years. This article reports two cases of reversible central hypothyroidism following the administration of the HIF-PHI roxadustat in patients undergoing regular hemodialysis with end-stage renal disease. Both patients gradually developed non-specific discomfort symptoms after one year of oral roxadustat treatment. Laboratory tests revealed abnormal thyroid function, while cranial magnetic resonance imaging showed no abnormalities. After discontinuation of roxadustat, thyroid function returned to normal and the symptoms resolved. These two cases suggest that it is necessary to monitor thyroid function in patients receiving oral roxadustat for renal anemia.

Key words: Hypoxia-inducible factor prolyl hydroxylase inhibitor, Roxadustat, Central hypothyroidism, Hemodialysis, Renal anemia

CLC Number:

R595.3

XIA Yumiao, FU Peng, WU Hao. Roxadustat-induced central hypothyroidism in hemodialysis patients: a report of two cases[J]. Journal of Internal Medicine Concepts & Practice, 2025, 20(06): 487-489.

References 11

[1]	Yamashita C , Hirai Y , Nishigaito T , et al. Roxadustat and transfusional iron overload induced hypothyroidism in a hemodialysis patient:a case report with a literature review [EB/OL]. Ren Replace Ther, 2024. https://link.springer.com/content/pdf/10.1186/s41100-024-00537-z.pdf.
[2]	中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021, 101(20):1463-1502.
	Working Group of Guideline for Renal Anemia of Chinese Nephrologist Association of Chinese Medical Doctor Association. Chinese clinical practice guideline for the diagnosis and management of renal anemia[J]. Natl Med J China, 2021, 101(20):1463-1502.
[3]	Hashimoto M, Nagayama Y, Ichikura-Iida A, et al. Roxadustat-induced central hypothyroidism masked by uremia at the initiation of hemodialysis: a case report[J]. Cureus, 2024, 16(12):e76499
[4]	Omote D, Kuramoto N, Tomikawa A, et al. Roxadustat-induced central hypothyroidism in renal anemia patients: insights from antineutrophil cytoplasmic antibody-related vasculitis cases[J]. Cureus, 2024, 16(6):e61843
[5]	Haraguchi T, Hamamoto Y, Kuwata H, et al. Effect of roxadustat on thyroid function in patients with renal anemia[J]. J Clin Endocrinol Metab, 2023, 109(1):e69-e75. doi: 10.1210/clinem/dgad483
[6]	Kouki Y, Okada N, Saga K, et al. Disproportionality analysis on hypothyroidism with roxadustat using the Japanese adverse drug event database[J]. J Clin Pharmacol, 2023, 63(10):1141-1146. doi: 10.1002/jcph.2300
[7]	Tanaka H, Tani A, Onoda T, et al. Hypoxia-inducible factor prolyl hydroxylase inhibitors and hypothyroidism: an analysis of the Japanese pharmacovigilance database[J]. In Vivo, 2024, 38(2):917-922. doi: 10.21873/invivo.13519
[8]	闫雪莲, 唐冰颖, 曲璇, 等. 罗沙司他导致低促甲状腺激素性甲状腺功能减退一例[J]. 协和医学杂志, 2025, 16(2):519-522.
	Yan XL, Tang BY, Qu X, et al. A case report of hypothyrotropin hypothyroidism caused by roxadustat[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(2):519-522.
[9]	Nakano Y, Mitsuboshi S, Tada K, et al. Association between roxadustat use and suppression of thyroid function: a systematic review and meta-analysis[J]. J Pharm Health Care Sci, 2024, 10(1):30. doi: 10.1186/s40780-024-00351-z
[10]	Zheng X, Jin Y, Xu T, et al. Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: a cohort study[J]. Ren Fail, 2023, 45(1):2199093. doi: 10.1080/0886022X.2023.2199093
[11]	Kita S, Okuyama H, Kondo T, et al. Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat[J]. Clin Case Rep, 2024, 12(9):e9400. doi: 10.1002/ccr3.9400